Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA201 in Recurrent/Refractory Solid Tumors
NCT03247309Phase 1Completed
- Sponsor
- Immatics
- Start
- Dec 2018
- Primary completion
- Apr 2023
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of IMA201 in solid tumor, sponsored by Immatics. Primary endpoints: Incidence of adverse events at 3 years and Maximum Tolerated Dose at 21 days. Started Dec 2018; status: completed.
02
Drugs
IMA201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03247309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247309.